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Abstract Mental retardation (MR) is displayed by 57% of
NF1 patients with microdeletion syndrome as a result of
17q11.2 region haploinsufficiency. We considered the
cyclin-dependent kinase 5 regulatory subunit 1 (CDK5R1)
and oligodendrocyte-myelin glycoprotein (OMG) genes,
mapping in the NF1 microdeleted region, as candidate
genes for MR susceptibility. CDK5R1 encodes for a
neurone-specific activator of cyclin-dependent kinase 5
(CDK5) involved in neuronal migration during central
nervous system development. OMG encodes for an
inhibitor of neurite outgrowth by the binding to the
Nogo-66 receptor (RTN4R). CDK5R1 and OMG genes
are characterized by large 3′ and 5′ untranslated regions
(UTRs), where we predict the presence of several tran-
scription/translation regulatory elements. We screened
100 unrelated Italian patients affected by unspecific MR
for mutations in CDK5R1 and OMG coding regions and in
their 3′ or 5′ UTRs. Four novel mutations and two novel
polymorphisms for CDK5R1 and three novel mutations
for OMG were detected, including two missense changes
(c.323C>T; A108V in CDK5R1 and c.1222A>G; T408A
in OMG), one synonymous codon variant (c.532C>T;
L178L in CDK5R1), four variants in CDK5R1 3′UTR and
two changes in OMG 5′UTR. All the mutations were
absent in 370 chromosomes from normal subjects. The
allelic frequencies of the two novel polymorphisms in
CDK5R1 3′UTR were established in both 185 normal and
100 mentally retarded subjects. Prediction of mRNA and
protein secondary structures revealed that two changes
lead to putative structural alterations in the mutated
c.2254C>G CDK5R1 3′UTR and in OMG T408A gene
product.
Keywords Non-syndromic mental retardation . 17q11.2 .
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regulatory elements
Introduction
Mental retardation (MR) is a condition affecting 2–3% of
the general population [1, 2]. Non-syndromic MR, without
other clinical manifestations and with apparently normal
brain development, is the most common cognitive dys-
function, and its molecular basis is still poorly understood.
Most of the known genes found to be involved in non-
syndromic MR map to the X chromosome, and only
recently, a mutation in the neuronal serine protease neuro-
trypsin gene (PRSS12) and a mutation in the cereblon gene
(CRBN) have been associated with autosomal recessive
non-syndromic MR [1, 2]. These genes, mapped to
chromosomes 4 and 3, respectively, result the only au-
tosomal genes so far demonstrated to be involved in MR.
Due to the complexity of the central nervous system and
to the fact that the pathogenesis of MR can be only partially
explained by the known genes, additional genes are
expected to have a role in MR.
We have recently reported evidence that MR is sig-
nificantly more frequent in NF1 patients with microdele-
tion syndrome than in those with classic NF1 (57 vs 4–8%)
[3]. This evidence suggests that hemizygosity of one or
more genes within the deleted region might be involved in
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the onset of MR and points to 17q11.2 as a further
autosomal candidate region for MR.
Among the genes within the 17q11.2 deleted region,
which are known to be involved in the development or in
the correct function of central nervous system, we se-
lected the cyclin-dependent kinase 5 regulatory subunit
1 (CDK5R1) and oligodendrocyte-myelin glycoprotein
(OMG) genes as potential candidates for MR.
Cyclin-dependent kinase 5 regulatory subunit 1 (CDK5R1)
encodes for p35, a neurone-specific activator of cyclin-de-
pendent kinase 5 (CDK5), whose activity plays a central
role in neuronal migration during central nervous system
development [4]. Cdk5r KO mice have severe cortical
lamination defects and suffer from adult mortality and
seizures [5–7]. The active CDK5–p35 complex is involved
in several processes required for central nervous system
development and function such as axonal regeneration [8],
cellular differentiation, neuronal apoptosis [9], learning and
memory processes [10], synaptic transmission [11] and
membrane trafficking during the outgrowth of neuronal
processes [12]. Moreover, increased CDK5 activation by
p25, a proteolytic fragment containing the C-terminal
portion of p35, has been implicated in the pathogenesis of
several neurodegenerative disorders, such as Alzheimer’s
disease [13], Parkinson’s disease [14] and amyotrophic
lateral sclerosis [15].
In addition, the CDK5R1 gene displays a large 3′
untranslated region (UTR). Extended UTR length provides
significant potential for transcript-specific regulation orig-
inating in this region [16]. UTR sequences are known to
play crucial roles in the post-transcriptional regulation of
gene expression, including modulation of mRNA transport
out of the nucleus, and of translational efficiency [17],
subcellular localization [18] and stability [19]. Moreover,
several regulatory elements have already been identified
in 3′UTR and are considered as hot spots for pathology
[20, 21].
OMG encodes for a protein that has been shown to be a
potent inhibitor of neurite outgrowth by the binding to the
Nogo-66 receptor (RTN4R), a protein associated with
myelin [22], recently suggested as one of the genetic causes
predisposing to schizophrenia [23]. The OMG gene was
found to be highly expressed during the late stages of
myelination in the rat central nervous system, indicating
that it could be important for a proper myelination process
[24]. The OMG 5′UTR is very large, raising the possibility,
as for CDK5R1, that this region could bear UTR regulatory
elements or, alternatively, upstream AUG codons (uAUG)
and upstream open reading frame (uORF), which have
been recently shown to act in the control of the translation
process [25].
We performed mutation analysis of CDK5R1 and OMG
genes in 100 patients with non-syndromic MR to verify the
presence of rare alleles with a possible functional sig-
nificance in MR condition. Following the prediction of
several regulatory elements in the CDK5R1 and OMG
UTRs, we carried out the mutation study in both the coding
regions and the predicted UTR regulatory elements. Here,
we report four novel mutations and two novel polymor-
phisms for CDK5R1 and three novel mutations for OMG.
Materials and methods
Subjects
The patient panel used for the mutation screening consisted
of 100 subjects with unexplained MR, as the most common
genetic causes of MR (chromosome rearrangements, ab-
normalities in blood and urine amino acids, urine organic
acids, Fragile X, Angelman and Rett syndromes) were
previously excluded.
The group of patients analysed was made up of 42 males
and 58 females: 30 were familial cases, whereas 70 were
apparently sporadic cases.
With few exceptions, participants were younger than
18 years (2–53 years), most of them between 5 and 10 and
all were Caucasian.
Genomic DNA samples were provided by the Labora-
tory of Medical Cytogenetics and Molecular Genetics of
the Istituto Auxologico Italiano (Milan), to which the
patients were referred by internal or external clinicians in
the period from 1995 to 2004.
We used the definition of MR provided by the American
Association on Mental Retardation [26]; severity was
categorized according to the World Health Organization
classification (1968) and the Diagnostic and Statistical
Manual (4th rev.) (DSM-IV) [27]. Children with severe
(35 < IQ< 20) and profound (IQ ≤ 20) MR were grouped
together in a single category.
Formal IQ values were accessible and previously
obtained by administering one of the Wechsler scales or
the Leiter International Performance Scale in non-verbal
subjects or the Griffiths Developmental Scales in younger
children.
One third of patients were previously referred for
Angelman syndrome genetic screening due to absence of
speech, severe to profound MR (IQ< 35) and seizures or
abnormal EEG. As for the remaining two thirds of patients,
severity of MR ranged from mild (70 < IQ< 55) to
moderate (54 < IQ< 36), and they were referred for Fragile
X molecular testing. All the patients, regardless of their
cognitive impairment, had a history of speech and language
delay. Most of them also had a history of psychomotor
delay and displayed short attention span and behavioural
abnormalities suggesting, or fitting, the autism spectrum of
disorders.
Fragile X testing was subsequently carried out on the
whole patient panel, regardless of the reason for sample
referral. Mecp2 was further investigated in the six females
referred for Angelman syndrome methylation testing [28],
and all of them had a history of psychomotor delay and
severe language disabilities. The above two tests resulted
negative in all these patients.
Subtelomeric rearrangements were ruled out in subjects
with family history for MR and in those with dysmorphic
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facial features. A few patients displayed, beside MR,
additional isolated dysmorphic facial features, which
however did not fit a specific syndromic pattern.
All the control subjects were Caucasian.
Mutation analysis
CDK5R1 coding sequence (consisting of a single exon)
was amplified in two overlapping PCR fragments termed
CDK5R1-CDS.1 and CDK5R1-CDS.2. OMG coding
sequence (a single exon also) was amplified in three
overlapping PCR fragments termed OMG-CDS.1, OMG-
CDS.2 and OMG-CDS.3. Three additional fragments were
designed to cover the AU-rich and GY-box elements in the
3′UTR of CDK5R1 (named CDK5R1-3′UTR.1 and
CDK5R1-3′UTR.2) and exon 1 in the 5′UTR of OMG
(named OMG-5′UTR) (Table 1). Primers used in this study
were designed using the Oligo 4.0 software and are listed in
Table 1.
PCR was carried out in 50 μl reaction volumes
containing 100 ng of genomic DNA, 0.2 μM primers,
100 μM dNTPs, 5 μl reaction buffer, 50 mM MgCl2 and
2.5 U BIOTAQ DNA Polymerase (Bioline) with the
following cycling profile: 4 min initial denaturation at
95°C, 35 cycles as follows: denaturation at 95°C for 30 s,
specific annealing temperature for 30 s (Table 1), extension
at 72°C for 30 s. The specificity of the amplified PCR
products was checked by 1.5% agarose gel electrophoresis.
PCR products of both patients’ and controls’ DNAwere
directly sequenced in both directions using the Big Dye
Terminator kit (Applied Biosystem) and resolved on a 3100
ABI Prism Genetic Analyzer (Applied Biosystem, Foster
City, CA). All the variations detected were confirmed on a
second PCR product.
In silico analysis
Reference sequences of the CDK5R1 and OMG genes were
retrieved from the NCBI Refseq Project (http://www.ncbi.
nlm.nih.gov/RefSeq/).
Functional regulatory elements in CDK5R1 and OMG
UTRs were searched by means of UTRScan, a program
that looks for UTR functional elements by searching for the
patterns defined in the UTRsite collection (http://bighost.
area.ba.cnr.it/BIG/UTRHome/).
Multiple alignment of protein sequences was performed
with Clustal X, a windows interface for the ClustalW
multiple sequence alignment program (ftp://ftp-igbmc.u-
strasbg.fr/pub/ClustalX/).
For protein secondary structure prediction, we used the
PSIPRED Protein Structure Prediction Server (http://bioinf.
cs.ucl.ac.uk/PSIPRED/psiform.html), while the GlobPlot
web service was used to determine the propensity to order/
globularity and disorder of the proteins and to explore
globular domains (http://globplot.embl.de/).
CDK5R1 3′UTR secondary structure was calculated by
means of Mfold, a web server for nucleic acid folding
prediction (http://www.bioinfo.rpi.edu/applications/mfold/
old/rna/). The reference secondary structure of the
CDK5R1 3′UTR was retrieved in the UCSC Genome
Browser (http://genome.ucsc.edu/).
The splice site prediction was performed with Splice
View (http://l25.itba.mi.cnr.it/~webgene/wwwspliceview.
html) and with NNSPLICE0.9 (http://www.fruitfly.org/
seq_tools/splice.html).
Results and discussion
One hundred MR patients were analysed for mutations in
CDK5R1 and OMG genes using direct sequencing. The
sequence analysis was carried out for the coding regions
and for parts of the UTRs, selected for the presence of
predicted UTR regulatory elements. This study allowed us
to identify four novel mutations and two novel polymor-
phisms in CDK5R1 and three novel mutations in OMG. All
the mutations were heterozygous, and none was found in a
sample of 370 healthy chromosomes. The frequencies of
the novel and known polymorphisms were estimated in
both MR patients and 185 controls.
Table 2 summarizes novel and known mutations and
polymorphic changes identified in this study. Mutation no-
menclature refers to the NCBI RefSeq cDNAs NM_003885
(CDK5R1) and NM_002544 (OMG).
Two novel mutations, c.323C>T (p.A108V), c.532C >T
(p.L178L) and one known c.904C>A (p.L302I), were
Table 1 Primer sequences, amplicon size and PCR annealing temperature for CDK5R1 and OMG fragments
Primer name Forward primer, reverse primer Size (bp) PCR annealing (°C)
CDK5R1-CDS.1 5′-TCGGTGAGCGGTTTTATCCC-3′, 5′-ACAGGTGCTTCAGGCGGTAG-3′ 587 63
CDK5R1-CDS.2 5′-GTCATCGTCCAGGCGTCC-3′, 5′-GCTCGTGAGTTCAAAAGTGC-3′ 681 63
CDK5R1-3′UTR.1 5′-GTTTCCACCTTACCCTACTG-3′, 5′-GTGCTGTGTGAAGTCTGTG-3′ 521 60
CDK5R1-3′UTR.2 5′-CCACAGGAATAATAGTTCAGG-3′ 527 56
5′-CCCCAATAACACAAATCCAAT-3′
OMG-5′UTR 5′-GAAAACTATCCATGAGGAAGG-3′, 5′-TATCCCTCAACTGACACTGC-3′ 613 58
OMG-CDS.1 5′-GGAGTGCTTTCATTAGTTTCA-3′, 5′-CACACCTTCTGGATTTACCT-3′ 555 57
OMG-CDS.2 5′-GTTTGGGTATTTTGGTCACTT-3′, 5′-TCTCAACCTCAGTAGTAACAA-3′ 467 57
OMG-CDS.3 5′-ATGTACCTGGAAGAATTTGTG-3′, 5′-TTTGCCTAATGCTAACTGACC-3′ 646 57
61
identified in the CDK5R1 coding sequence. The first
variation (c.323C>T), found in patient MR-82, results in
the substitution of alanine 108 by valine (p.A108V). This
amino acid is positioned within a proline-rich region of p35
which is perfectly conserved in mammals, while displaying
marked differences in other organisms, as shown by the
multiple alignment performed with the ClustalX program
(Fig. 1a). No 3-D structure data are available for this
region, which is likely to serve as link between two
functional domains of the protein, as suggested by the
analysis with the GlobPlot and PSIPRED software (data
not shown), as well as by the alignment itself. The
substitution from alanine to valine is conservative; how-
ever, the PSIPRED analysis predicts the lack of two short
helices 46 amino acids upstream and 2 amino acids
downstream the A108V mutation (data not shown).
The A108V change involves a residue situated in
position +10 with respect to the cleavage site of the calpain
protease, which generates the p35 proteolytic fragment
p25. In a recent work, a consensus sequence was identified
around the scissible bond from the position −4 to the
position + 7 [29]. Even if the mutation falls outside the
critical region, a potential effect on the calpain cleavage
efficiency cannot be ruled out, taking into account the
vicinity of the mutated residue to the cleavage site. In
addition, the high conservation of the affected region is
indicative of a possible role in the regulation of CDK5/
CDK5R1 activity, thus suggesting to further investigate a
possible effect of the identified variation.
The second sequence change (c.532C>T) is a synon-
ymous substitution of leucine 178 (p.L178L) in the domain
of binding to the CDK5 kinase. Interestingly, both
c.323C>T (p.A108V) and c.532C>T (p.L178L) mutations
were found in the same patient (MR-82), who displays MR
and cognitive dysfunction.
Another change, c.904C>A, was found in the coding
region of CDK5R1. This causes the substitution of leucine
302 with isoleucine (p.L302I) at the C terminus of the
protein. Leucine 302 is a conserved residue in CDK5R1
vertebrate orthologs, but the PSIPRED Server does not
predict any change in the protein secondary structure. This
mutation was found in patient MR-9, who displays
psychomotor and development delay, MR, speech and
language impairment and microcephalia. This mutation
was previously reported by Kam et al. [30], who observed
the variation in the constitutional DNA of a patient who
developed ganglioglioma.
Because of the exceptional extent of CDK5R1 3′UTR
(>2.5 kb), the presence of UTR regulatory elements is
expected. Sequence and structural elements located in the
UTRs of mRNA are known to play significant roles in
translational regulation. These regions are defined as cis-
regulatory elements, and they regulate mRNA stability and
translational efficiency by acting as binding sites for trans-
acting cytoplasmic factors [31]. In addition, several
regulatory elements have been described in 3′UTR for
most of which a pathogenetic role has been demonstrated
[20, 21].
We thus performed a bioinformatic analysis of CDK5R1
3′UTR by means of UTRScan and predicted a GY-box
motif (GUCUUCC) at position 2,264–2,270 on the cDNA
and a region in the last 200 nt of the transcript showing
three putative AU-rich elements (Fig. 2).








CDK5R1 Coding c.323C>T p.A108V – Sporadic This study
CDK5R1 Coding c.532C>T p.L178L – Sporadic This study
CDK5R1 Coding c.904C>A p.L302I – Sporadic (1) and this
study
CDK5R1 3′UTR c.1005G>A – pts: fr(G)=0.995, fr(A)=0.005; c: fr(G)=0.995, fr(A)
=0.005
Sporadic This study
CDK5R1 3′UTR c.1043G>A – pts: fr(G)=0.690, fr(A)=0.310; c: fr(G)=0.725, fr(A)
=0.275
Sporadic (2) and this
study
CDK5R1 3′UTR c.2160C>T – pts: fr(C)=0.975; fr(T)=0.025; c: fr(C)=0.960, fr(T)
=0.040
Sporadic This study
CDK5R1 3′UTR c.2254C>G – – Familial This study
CDK5R1 3′UTR c.3452G>A – – Sporadic This study
OMG 5′UTR c.−1028A>C – – Sporadic This study
OMG 5′UTR c.−734A>G – – Sporadic This study
OMG Coding c.62G>A p.G21D pts: fr(G)=0.910, fr(A)=0.090; c: fr(G)=0.875, fr(A)
=0.125
Sporadic (3) and this
study
OMG Coding c.1222A>G p.T408A – Familial This study
Novel variants are in bold. Nucleotide positions refer to CDK5R1 cDNA (accession no. NM_003885) and OMG cDNA (accession no.
NM_002544)
(1) Kam et al. [30], (2) refSNP ID: rs8192474 (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Snp), (3) Vourc’h et al. [36]
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GY-box motif has first been described in many 3′UTRs
of genes involved in Notch signalling in Drosophila where
it mediates negative post-transcriptional regulation [32].
GY-box motif is complementary to the 5′ end of some
Drosophila microRNA (miRNAs) and has been validated
as a miR-7 target [33]. Transcripts bearing the GY-box are
negatively regulated by complementarity to the corre-
sponding miRNAs in vivo [34]. The 3′UTR of CDK5R1
mRNA also includes potential sequence elements such as
the AUUUA pentamer and other AU-rich regions, known
to play a role in mRNA stability and degradation through
the binding to specific factors [31].
We thus sequenced the two portions of 3′UTR of
CDK5R1 gene in which putative regulatory elements (GY-
box and AU-rich elements) were predicted. Two novel
mutations were found in these regions: c.2254C>G and
c.3452G>A. Notably, the nucleotide change c.2254C>G
is only 10 bp upstream of the GY-box element. The
secondary structure of CDK5R1 3′UTR was predicted with
Mfold and compared with the normal structure available
from the UCSC Genome Browser. This analysis allowed us
to see a significantly different folding of the RNA in
the portion surrounding residue 2254G compared with the
wild-type residue 2254C (Fig. 1b,c). This change in the
RNA secondary structure causes a different positioning of
the GY-box element which may affect its correct function-
ing. The mutation was found in patient MR-44 and in her
mother, who also displays MR. Apart from the proband and
her mother, three other mentally retarded sibs, one of
whom generated a MR child, were in this pedigree, but
unfortunately, no further family members were available to
verify segregation of the mutation with the MR. Mutation
c.3452G>A was found in patient MR-74, who displays
MR, language retardation, isolation propensity and atten-
tion deficit. The variation is located in the AU-rich portion
but outside the predicted AU-rich elements of the 3′UTR of
CDK5R1. Indeed, no differences in 3′UTR folding were
predicted using Mfold, compared with the wild-type
structure. Further studies are required to determine whether
this mutation falls inside an as yet unknown UTR reg-
ulatory element and whether the nucleotide change might
affect the regulation of transcript degradation.
Fig. 1 a Multiple alignment of p35 amino acid sequence from
human (Homo sapiens, Hom), mouse (Mus musculus, Mus), rat
(Rattus norvegicus, Rat), cow (Bos taurus, Bos), zebra fish (Danio
rerio, Dan) and green spotted pufferfish (Tetraodon nigroviridis,
Tet), from amino acid 83 to amino acid 146. Box indicates Ala 108.
Stars represent fully conserved residues, single/double dots indicate
the presence of specific amino acid groups, according to the
ClustalX classification. b, c Prediction of the CDK5R1 3′ un-
translated region (UTR) secondary structure in the region compris-
ing the GY-box, using the Mfold tool. b Wild-type structure in
accordance with the secondary structure reported in UCSC database.
c Prediction of the mutated (2254G) 3′UTR secondary structure. The
free energy decrease is indicated. d, e Prediction of the secondary
structure of OMgp (shown from amino acid 361 to amino acid 440)
using the PSIPRED tool. Arrows indicate Thr 408 in the wild-type
sequence (d) and Ala 408 in the mutated sequence (e). Cylinders
and arrows indicate the potential α-helix or β-sheet structures,
respectively. The vertical bars indicate the level of the prediction
confidence
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In addition, within the sequenced 3′UTR fragments, two
novel rare polymorphisms were found (c.1005G>A and
c.2160C>T). The rare allele 1005A was observed in one
patient and one normal control only, while the rare allele
2160C showed a frequency of 0.025 in the MR patients and
of 0.04 in the control sample (370 chromosomes). We also
calculated the allelic frequencies of the known polymor-
phism c.1043G>A (ref SNP ID: rs8192474) in our cohort
of MR patients which were found not to significantly differ
from those in 185 control chromosomes and those
registered in online databases.
As regards the OMG gene, we found in its coding region
a novel mutation c.1222A>G (p.T408A) in patient MR-27,
who displays MR and language impairment. This mutation
leads to the substitution to alanine of threonine 408, which
is positioned in the S/T-rich domain of the protein and is
conserved in several mammal species [35]. Secondary
structure and function of this domain are not known.
Secondary structure prediction of the OMgp protein with
PSIPRED shows that p.T408A substitution might cause
conformation changes in the surrounding regions, in
particular in the short hydrophobic region at C terminus
of the protein (Fig. 1d,e). We looked for the variation in the
DNA of the parents of patient MR-27 which was found in
the unaffected mother. A possible incomplete penetrance of
the phenotype might explain the finding of the p.T408A
substitution in a normal carrier, and this does not
necessarily exclude a disease causative role for the
mutation.
We also evaluated the allelic frequencies of the known
polymorphism c.62G>A (p.G21D) in both patients and
controls, which were found to be similar to those reported
by Vourc’h et al. [36].
We extended the mutation analysis to OMG 5′UTR,
which is characterized by a large size, including an intron,
where nine uAUG and seven predicted uORFs were found.
uORFs are recognized and translated by ribosomes and
have been proposed to act in the control of translation by
means of different mechanisms, e.g. altering the mRNA
stability or causing the ribosome to stall during the
elongation/termination phase of uORF translation, creating
a blockade to additional ribosome scanning [25]. However,
no 5′UTR regulatory elements were predicted using the
UTRScan program.
We detected in this region two novel mutations (c.
−1028A>C and c.−734A>G). Mutation c.−1028A>C,
which abolishes a stop codon not belonging to any
predicted uORF, was found in patient MR-75, who
displays MR, speech and language impairment, short
attention span and hyperactivity. Mutation c.−734A>G, in
patient MR-71, showing isolated MR, is localized within
the IVS between exon 1 and exon 2. No effect of this
mutation on splice sites was predicted by analysis with
Splice View and NNSPLICE0.9.
The sequence alterations identified in CDK5R1 and
OMG genes have been classified according to the allele
frequencies as mutations and polymorphisms. We think
that the observed sequence changes might concur with
variation at other loci in the susceptibility to MR and/or
neurodegenerative diseases.
Mutation screening of CDK5R1 and OMG enhanced
definition of the repertoire of their variant alleles which
might help future association studies.
In addition, a possible synergic role of the two gene
products in the central nervous system development may























































Fig. 2 3′UTR sequence of the
CDK5R1 cDNA, from nucleo-
tide 1831 to poly-A tail. The
GY-box element is shaded,
while AU-rich elements are
boxed. The amplicons used for
mutation analyses are indicated
in bold
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common signal transduction pathway: together with other
ligands of the RTN4R receptor (e.g. myelin associated
glycoprotein, MAG), OMgp might stimulate the phos-
phorylation of neurofilaments (NFs) and microtubule-
associated proteins (MAPs) through the activation of the
CDK5/p35 complex [37].
Moreover, findings from this study might help in
addressing the functional analysis of both the regulatory
transcriptional elements of UTRs and the gene products.
Further investigations are necessary to establish whether or
not the reported mutations cause a decreased activity of the
respective gene products. A gene product dosage-depen-
dent effect of mutated genes would simulate the effect of
the pathogenetic mechanism based on gene haploinsuffi-
ciency reported for microdeletion syndromes.
In perspective, a better assessed role of CDK5R1 and
OMG in MR might enhance the genotype–phenotype
correlation in patients with NF1 microdeletion syndrome.
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